文献速递肝病消化道肿瘤与早癌

aMAP风险评分预测慢性肝炎患者肝细胞癌发生

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
PubMed 文献 · J Hepatol · 2020-07-21

该国际协作研究基于11个前瞻性队列或随机对照试验的17374例慢性肝炎患者,开发并验证了仅含年龄、男性、白蛋白-胆红素和血小板的aMAP评分(0-100分)。评分在不同病因和种族中区分度良好(C-index 0.82-0.87),50和60为最佳截断值,低、中、高危组3年或5年肝细胞癌累积发生率分别为0-0.8%、1.5-4.8%和8.1-19.9%。

要点

  • aMAP评分仅含年龄、男性、白蛋白-胆红素和血小板,范围0-100分。
  • 评分在训练和验证队列中C-index为0.82-0.87,不受病因和种族影响。
  • 低、中、高危组3年或5年肝细胞癌累积发生率分别为0-0.8%、1.5-4.8%和8.1-19.9%。

核心结论

  • 该客观、简单、可靠的风险评分基于5个常见参数,无论病因和种族均能准确预测肝细胞癌发生,有助于建立全球风险评分指导的肝细胞癌监测策略。

研究设计与样本

  • 国际协作研究,共纳入17374例患者,来自11个国际前瞻性观察队列或随机对照试验,分为训练队列(3688例亚洲慢性乙型肝炎患者)和9个不同病因及种族的验证队列(n=13686)。

主要发现

  • aMAP评分在评估不同病因肝炎及不同种族患者的肝细胞癌风险中表现优异,C-index为0.82-0.87。
  • 50和60为区分肝细胞癌风险的最佳截断值。
  • 低危组(n=7413,43.6%)、中危组(n=6529,38.4%)和高危组(n=3044,17.9%)的3年或5年肝细胞癌累积发生率分别为0-0.8%、1.5-4.8%和8.1-19.9%。
  • 截断值50对应的敏感性为85.7-100%,阴性预测值为99.3-100%。
  • 截断值60对应的特异性为56.6-95.8%,阳性预测值为6.6-15.7%。

关键数值与推荐

  • aMAP评分范围为0-100分,仅包含年龄、男性、白蛋白-胆红素和血小板。
  • 截断值50和60为区分肝细胞癌风险的最佳值。
  • 截断值50的敏感性为85.7-100%,阴性预测值为99.3-100%。
  • 截断值60的特异性为56.6-95.8%,阳性预测值为6.6-15.7%。

临床怎么用

  • aMAP评分可用于不同病因和种族慢性肝炎患者的肝细胞癌风险预测,有助于建立风险评分指导的肝细胞癌监测策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis. METHODS: A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686). RESULTS: We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%. CONCLUSIONS: This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide. LAY SUMMARY: In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020. PMID: 32707225. doi:10.1016/j.jhep.2020.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。